Crystalline Polymorphs of a BTK Inhibitor for Stable Manufacturing
Solution Overview
Problem
There is a need for effective inhibitors of Bruton's tyrosine kinase (Btk) to treat autoimmune disorders and other conditions related to B-cell and T-cell signaling, with a focus on improving stability, pharmacokinetic properties, and suitability for pharmaceutical uses.
Innovation Solution
Development of crystalline polymorphs of N-methyl-N-((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide, including forms A, B, maleate, tartrate, citrate, and proline salts, characterized by specific PXRD, DSC, and TGA profiles, to enhance stability and suitability for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If amorphous or non-crystalline forms of the compound are used, then the compound can be obtained more easily, but the stability and suitability for pharmaceutical uses are reduced
Solution Approach 1:
The patent applies parameter changes by transforming the physical state of the compound from amorphous to crystalline forms with specific polymorphic structures. Different crystalline forms (Forms 1-6) are obtained by controlling crystallization parameters such as solvent selection, temperature, and pH conditions during salt formation. This transformation to defined crystalline structures significantly improves stability while maintaining manufacturability through controlled crystallization processes.
Solution Approach 2:
The patent utilizes phase transitions by forming crystalline salts from the compound through controlled crystallization processes. The transition from amorphous compound to ordered crystalline lattice structures (evidenced by specific PXRD patterns) enhances stability. Different salt forms (maleate, tartrate, citrate, proline salts) represent different phase transitions achieved through reaction with specific acids or amines followed by crystallization.
2Reliability
If multiple crystalline polymorphs are developed, then stability and pharmacokinetic properties are improved, but the complexity of the system increases
Solution Approach 1:
The patent applies segmentation by dividing the single compound into multiple distinct crystalline polymorphs and salt forms, each with specific characteristics. Forms 1-6 represent segmented crystalline structures with different PXRD patterns, melting points, and stability profiles. This segmentation allows selection of optimal forms for specific pharmaceutical applications while maintaining clear structural definitions for each form.
Solution Approach 2:
The patent uses parameter changes to differentiate between multiple crystalline forms by controlling crystallization conditions such as solvent type, temperature, pH, and concentration. Each polymorph and salt form is obtained under specific parameter conditions, allowing systematic development of multiple forms with tailored properties for different pharmacokinetic requirements without arbitrary complexity.
3Stability of the object's composition
If crystalline polymorphs with specific structures are prepared, then stability and pharmacokinetic properties are enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-defining specific crystallization conditions and salt formation protocols for obtaining each polymorph and salt form. The manufacturing process incorporates preliminary steps such as selecting appropriate solvents, controlling pH ranges, and setting temperature profiles before crystallization occurs. This preliminary planning simplifies the actual manufacturing execution while ensuring reproduction of the desired stable crystalline forms.
Solution Approach 2:
The patent manages manufacturing complexity through systematic parameter changes that define clear boundaries for obtaining each crystalline form. By establishing specific parameter ranges (solvent types, temperatures, pH values, concentrations), the patent creates reproducible manufacturing protocols for each polymorph and salt form, transforming what could be complex trial-and-error processes into defined manufacturing procedures.
Data Source
AI summary
Provided are crystalline forms of N-methyl-N-((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide, pharmaceutical compositions, methods of use and methods of making thereof.